MedWatch

Future uncertain for Orphazyme CEO as firm sold

Although the plan is that the majority of Orphazyme’s 20 remaining employees will now work for the new owner, US-based Kempharm, it is not yet clear whether CEO Anders Vadsholt will join them, he tells MedWatch.

Anders Vadsholt, CEO, Orphazyme | Photo: Orphazyme / PR

Since the start of March, CEO Anders Vadsholt has guided listed biotech company Orphazyme through choppy waters, but it is far from certain that he will make the voyage across the Atlantic to join the firm’s new owners, Kempharm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs